Triple therapy vs. dual bronchodilator therapy for chronic obstructive pulmonary disease: Is it worth the cost?

Respiratory Investigation

Volumn 53, Issue 4, 2015, Pages 173-175

  Horita, Nobuyuki ^a   Kaneko, Takeshi ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT;

CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; DATA ANALYSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; FORCED EXPIRATORY VOLUME; HEALTH IMPACT ASSESSMENT; HIGH RISK POPULATION; HUMAN; LETTER; MEDICAL RESEARCH; MORTALITY; OUTCOME ASSESSMENT; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; COMBINATION DRUG THERAPY; ECONOMICS; INHALATIONAL DRUG ADMINISTRATION; META ANALYSIS (TOPIC); PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; FORCED EXPIRATORY VOLUME; HUMANS; META-ANALYSIS AS TOPIC; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84931569189     PISSN: 22125345     EISSN: 22125353     Source Type: Journal    
DOI: 10.1016/j.resinv.2015.01.006     Document Type: Letter

References (12)

1. Global Initiative for Chronic Obstructive Lung Disease 2014. Global strategy for diagnosis, management, and prevention of COPD. Available from: ; 2014 [accessed 21.12.14]. http://www.goldcopd.org/.
2. COPD guideline for diagnosis and treatment 2013, Japanese Respiratory Society, Tokyo Japan, (Japanese). 4th ed.
3. Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: the case against. Eur Respir J 2009, 34:13-16.
4. Drummond MB, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. J Am Med Assoc 2008, 300:2407-2416.
5. Yang IA, Clarke MS, Sim EH, et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012, 7:CD002991.
6. Price D, West D, Brusselle G, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis 2014, 9:889-904.
7. Karner C, Cates CJ. The effect of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011, 9:CD009039.
8. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007, 146:545-555.
9. Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014, 371:1285-1294.
10. Najafzadeh M, Marra CA, Sadatsafavi M, et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax 2008, 63:962-967.
11. American Thoracic Society. Quality of life resource: minimal clinically significant difference. Available from: [accessed 15.01.15]. http://qol.thoracic.org/sections/measurement-properties/minimal-clinically-significant-difference.html.
12. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 2002, 19(Suppl. 3):S398-S404.